Scroll Back to Top
therascreen® PIK3CA Mutation Analysis (FDA approved)

Sponsored Testing Programs

Improving patient outcomes

We are proud to build partnerships in order to increase access and improve patient outcomes.  Through our oncology sponsored testing programs, we can empower better decisions for healthcare providers and help close the gap when it comes to cancer care for patients.  Labcorp Oncology currently offers sponsored testing programs for non-small cell lung cancer (NSCLC), acute myeloid leukemia (AML) and high risk myelodysplastic syndromes (MDS), and systemic mastocytocis for patients that meet the eligibility requirements.  

Sponsored Testing Programs

HLA today

HLA Today

For patients with AML or high risk myelodysplastic syndrome (MDS). The program aims to improve patient outcomes by providing physicians with critical information as early as possible. Offered by the NMDP/Be The Match in partnership with LabCorp, high-resolution HLA typing results and a preliminary donor search report will be sent at no-charge to providers or patients.

Mature woman

Blueprint’s Biomarker Testing Program

No-charge KIT D816V testing for Systemic Mastocytosis provided by Labcorp Oncology for eligible patients through the sponsored testing program from Blueprint Medicines. Early biomarker testing using a non-invasive, highly sensitive, and quantitative KIT D816V test may reduce a patient’s time to diagnosis. 

senior man

NSCLC Sponsored Testing Program

No-charge OmniSeq INSIGHTsm, genomic profiling testing, for NSCLC provided by Labcorp Oncology for eligible patients through the sponsored testing program from Lilly.  The program focuses on the value of broad testing via comprehensive genomic profiling and the potential benefits for patients.

Explore Our Test Menu

Our comprehensive menu features more than 450 single analyte and multi-marker tests to provide critical insights you need at every step of the patient journey.

Labcorp Lab

To learn more, please contact us